Renovaro Inc.

Renovaro Inc.

RENB - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$47.72M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Renovaro Inc.Renovaro Inc.-0.2-39%--0.1
$-0.37

Current Fair Value

126.1% downside

Overvalued by 126.1% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$47.72 Million
Enterprise Value$-327,558,177.00
Earnings per Share$-1.06
Beta0.53
Outstanding Shares33,609,030

Return

Return on Equity39.47%ROE
Return on Assets-35.83%
Return on Invested Capital96.98%

Valuation & Multiples

P/E Ratio-0.2P/E Ratio
PEG-0.01PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.01Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT0.04
Enterprise Value to Net Income0
Total Debt to Enterprise-3.91
Debt to Equity-0.15Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
February 17, 2026
EPS
-$0.08
Reported
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-▼ 100.00%
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %4.94%▲ 4.39%
Total Invested$981,267▼ 30.60%
Investors Holding210%

About Renovaro Biosciences Inc

11 employees
CEO: Eric Leire

enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the...